Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 17/20 | 0.57 |
| ▸ | PGR | P06401 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rofleponide SCHEMBL8505525 | 0.92 | NR3C1 (0.68) | NR3C1PGRLMNACYP3A4MAPT | |
| Rofleponide SCHEMBL74762 | 0.92 | NR3C1 (0.68) | NR3C1PGRLMNACYP3A4MAPT | |
| Rofleponide SCHEMBL23803954 | 0.92 | NR3C1 (0.68) | NR3C1PGRLMNACYP3A4MAPT | |
| Rofleponide SCHEMBL7196822 | 0.92 | NR3C1 (0.68) | NR3C1PGRLMNACYP3A4MAPT | |
| Rofleponide SCHEMBL5506220 | 0.92 | NR3C1 (0.68) | NR3C1PGRLMNACYP3A4MAPT | |
| Rofleponide SCHEMBL6449744 | 0.90 | NR3C1 (0.64) | NR3C1PGRLMNACYP3A4MAPT | |
| SCHEMBL4734726 | 0.86 | NR3C1 (0.70) | NR3C1PGRLMNACYP3A4MAPT | |
| SCHEMBL6329468 | 0.86 | NR3C1 (0.65) | NR3C1PGRLMNACYP3A4MAPT | |
| SCHEMBL8204804 | 0.85 | NR3C1 (0.67) | NR3C1PGRLMNACYP3A4MAPT | |
| SCHEMBL8674574 | 0.85 | NR3C1 (0.70) | NR3C1PGRLMNACYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070515-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-31 | — | — | US | disclosed |
| EP-0998484-B1 | METHOD OF IDENTIFYING COMPOUNDS HAVING REDUCED SYSTEMIC EFFECTS | GLAXO GROUP LTD (GB) | 2004-03-03 | — | — | EP | disclosed |
| US-20020019378-A1 | COMPOUNDS | GLAXO WELLCOME INC. | 2002-02-14 | — | — | US | disclosed |
| EP-0998484-A1 | THARAPEUTICALLY ACTIVE COMPOUNDS WITH LOW SYSTEMIC ACTIVITY DUE TO REDUCED HALF-LIFE | GLAXO GROUP LIMITED (GB) | 2000-05-10 | — | — | EP | disclosed |
| WO-1999001467-A2 | THERAPEUTICALLY ACTIVE COMPOUNDS WITH LOW SYSTEMIC ACTIVITY DUE TO REDUCE HALF LIFE | GLAXO GROUP LIMITED (GB) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019378-A1 | COMPOUNDS | ATP6V1E1, PSME1, ATP6V1H | NR3C1 495/4885PGR 711/4885LMNA 3880/4885 |
| US-20050070515-A1 | Compounds | LCT, LPO, LIPE | NR3C1 3143/4885PGR 3923/4885LMNA 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.